📊 TVRD Key Takeaways
Is Tvardi Therapeutics, Inc. (TVRD) a Good Investment?
Tvardi Therapeutics exhibits severe operational deterioration with a 66% YoY revenue collapse and unsustainable operating losses of -274.5%, indicating failed commercialization or partnership loss. Despite maintaining adequate liquidity (19.9M cash with 2.9 years of runway at current burn), the company faces existential risk without significant pipeline catalysts or capital restructuring, compounded by the inherent biotech execution risk and lack of management insider activity.
Why Buy Tvardi Therapeutics, Inc. Stock? TVRD Key Strengths
- Zero debt with 0.00x debt-to-equity ratio eliminates solvency risk in near term
- Cash represents 77% of total assets providing 2.9 years of operating runway at current burn rate
- Current and quick ratios above 2.0x indicate adequate liquidity for obligations
TVRD Stock Risks: Tvardi Therapeutics, Inc. Investment Risks
- Catastrophic 66% YoY revenue decline suggesting failed product commercialization or major partnership termination
- Unsustainable negative free cash flow of -6.9M annually with operating margin of -274.5% and no path to profitability visible
- Minimal revenue base (2.6M) with pharmaceutical sector risk indicates no commercially viable products
- Potential dilution imminent as cash runway of 2.9 years insufficient for typical biotech development timelines
- Zero insider Form 4 filings in 90 days signals low management confidence in company direction
Key Metrics to Watch
- Quarterly revenue stabilization or further decline trajectory
- Monthly cash burn rate and updated remaining runway calculations
- Clinical pipeline progress announcements and partnership or licensing developments
- Operating cash flow trend toward positive territory indicating operational improvements
- Gross margin expansion when revenue stabilizes indicating potential path to unit economics viability
Tvardi Therapeutics, Inc. (TVRD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.25x current ratio provides a solid financial cushion.
TVRD Profit Margin, ROE & Profitability Analysis
TVRD vs Healthcare Sector: How Tvardi Therapeutics, Inc. Compares
How Tvardi Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tvardi Therapeutics, Inc. Stock Overvalued? TVRD Valuation Analysis 2026
Based on fundamental analysis, Tvardi Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tvardi Therapeutics, Inc. Balance Sheet: TVRD Debt, Cash & Liquidity
TVRD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tvardi Therapeutics, Inc.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-11.42 indicates the company is currently unprofitable.
TVRD Revenue Growth, EPS Growth & YoY Performance
TVRD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $2.1M | -$4.9M | $-3.22 |
| Q3 2024 | $2.6M | -$12.5M | $-0.23 |
| Q2 2024 | $991.0K | -$20.0M | $-0.37 |
| Q1 2024 | $2.1M | -$26.7M | $-0.49 |
| Q3 2023 | $4.9M | -$4.2M | $-0.43 |
| Q2 2023 | $6.9M | -$4.2M | $-0.08 |
| Q1 2023 | $4.8M | -$26.7M | $-0.49 |
| Q3 2022 | $10.8M | -$1.0M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tvardi Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TVRD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tvardi Therapeutics, Inc. (CIK: 0001346830)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TVRD
What is the AI rating for TVRD?
Tvardi Therapeutics, Inc. (TVRD) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TVRD's key strengths?
Claude: Zero debt with 0.00x debt-to-equity ratio eliminates solvency risk in near term. Cash represents 77% of total assets providing 2.9 years of operating runway at current burn rate.
What are the risks of investing in TVRD?
Claude: Catastrophic 66% YoY revenue decline suggesting failed product commercialization or major partnership termination. Unsustainable negative free cash flow of -6.9M annually with operating margin of -274.5% and no path to profitability visible.
What is TVRD's revenue and growth?
Tvardi Therapeutics, Inc. reported revenue of $2.6M.
Does TVRD pay dividends?
Tvardi Therapeutics, Inc. does not currently pay dividends.
Where can I find TVRD SEC filings?
Official SEC filings for Tvardi Therapeutics, Inc. (CIK: 0001346830) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TVRD's EPS?
Tvardi Therapeutics, Inc. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TVRD a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Tvardi Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TVRD stock overvalued or undervalued?
Valuation metrics for TVRD: ROE of -46.9% (sector avg: 15%), net margin of -264.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TVRD stock in 2026?
Our dual AI analysis gives Tvardi Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TVRD's free cash flow?
Tvardi Therapeutics, Inc.'s operating cash flow is $-5.9M, with capital expenditures of $1.0M. FCF margin is -268.8%.
How does TVRD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -264.9% (avg: 12%), ROE -46.9% (avg: 15%), current ratio 2.25 (avg: 2).